Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We believe this is a positive sign for biotech which is also aligned with the interest we have received from prospective investors |
| We're encouraged by the fact that our first patient treated had a meaningful clinical response and established for the first time that non-viral TCR-T cells can bring hope to patients with high unmet clinical need |
| Through this strategy, we believe we can bolster our IP portfolio, strengthen our pipeline for next-gen TCRT, and potentially deliver effective treatments to a larger number of patients |
| That's the amendment that's really facilitated enrollment and has really kind of buoyed us and exciting |
| Investor engagement remains encouraging and evidence points to capital markets being supportive of transactions for companies with differentiated science |
| So the I&D amendment in the fourth quarter of 2022 was really excellent |
| That really has worked out pretty well especially after the introduction of the cryopreservation to our program which is well received by our PIs, which has really helped us out putting our schedule upfront into the calendar |
| These improvements have facilitated faster patient accrual |
| The building momentum and interest in our TCRT platform gives us great confidence in the potential value of our disruptive technology as we seek to revolutionize the treatment of solid tumors |
| We will strive to strengthen our IP position, generate partnering opportunities and increase the addressable market with this platform |
| We are also enjoying success identifying new TCRs in our Hunter program |
| Our screening match rate has grown to over 10% as a result and effectively doubled the potential addressable market |
| We are so proud of our Hunter platform and we have a very high success rate of TCR discovery |
| So the bioinformatics team is -- it's amazing how they harness the power of AI to really accelerate the throughput over there |
| We are very excited about our manufacturing platform |
| We are confident, based on recent conversations that our science will continue to be recognized by investors for what it is a unique and disruptive technology that has promised to be curative for solid tumors |
| We have introduced new bioinformatics capabilities and advanced lab equipment, which greatly increases screening rates, while maintaining our high TCR discovery success rate |
| I'm so proud of the team, who has more than doubled the screening pace over the past year and strongly believe that we will be successful in identifying valuable TCRs for Alaunos |
| Recent corporate and capital changes have supported our belief in the tremendous upside potential of this platform |
| We believe, our rapid and high throughput approach to generate proprietary TCRs potentially increases the value of the company's pipeline |
| We are proud of Hunter believe it offers significant advantages over traditional TCR discovery methods |
| There have been several partnering transactions announced recently in our space, and we believe this is a positive sign for TCR companies |
| We believe that, these enhancements will enable us to meet our program milestones this year |
| We've told our hard-working employees buckle your seatbelt low and tight around your waste and be prepared for an exciting ride |
| In addition to the exciting progress, we've made in the clinic and enhancements to our corporate structure, we're making significant progress towards expanding our industry-leading library of TCRs through the Hunter platform |
| As Alaunos is one of the most advanced TCR-T companies targeting driver mutations, we believe that un-encumbering our TCR-T assets, allows us to maximize the shareholder value and further facilitate partnering discussions |
| We believe that our innovative approach, targeting high-frequency driver mutations is the most promising therapy for solid tumors |
| We have worked to capitalize on the growing excitement and momentum around this trial |
| And so we're quite excited about that part of the Hunter platform as well |
| Our accelerated enrollment compared to the prior year highlights the enthusiasm shared by the prospective patients |
| Statement |
|---|
| Actual results could differ materially from those stated or implied by the forward-looking statements made today due to risks and uncertainties associated with the company's business |
| For the first quarter of 2023 we reported a net loss of approximately $10 million or a $0.04 net loss per share compared to a net loss of approximately $9.8 million or a $0.05 net loss per share for the same period in 2022 |
| And Kevin second question, if I heard correctly nine to 12 patients are expected to be dosed by end of the year to complete Phase 1, which seems lower than the 12 to 15 patients target noted previously |
| General and administrative expenses were approximately $3.2 million for the first quarter of 2023, compared to approximately $3.5 million for the same period in the prior year, a decrease of 10% which was primarily due to lower professional fees as we continue to be focused on being good stewards of capital |
Please consider a small donation if you think this website provides you with relevant information